|
|
Previous Article | Table of Contents | Next Article 
Interleukin-12 Preserves the Graft-Versus-Leukemia Effect of Allogeneic CD8 T Cells While Inhibiting CD4-Dependent Graft-Versus-Host Disease in Mice
Yong-Guang Yang,
Justin J. Sergio,
Denise A. Pearson,
Gregory L. Szot,
Akira Shimizu, and
Megan Sykes
From the BMT Section, Transplantation Biology Research Center, Surgical Service, Massachusetts General Hospital/Harvard Medical School, Boston, MA.
We have recently demonstrated that a single injection of 4,900 IU of interleukin-12 (IL-12) on the day of bone marrow transplantation (BMT) markedly inhibits acute graft-versus-host disease (GVHD) in a fully major histocompatibility complex plus minor antigen-mismatched BMT model (A/J B10, H-2a H-2b), in which donor CD4+ T cells are required for the induction of acute GVHD. We show here that donor CD8-dependent graft-versus-leukemia (GVL) effects against EL4 (H-2b) leukemia/lymphoma can be preserved while GVHD is inhibited by IL-12 in this model. In mice in which IL-12 mediated a significant protective effect against GVHD, marked GVL effects of allogeneic T cells against EL4 were observed. GVL effects against EL4 depended on CD8-mediated alloreactivity, protection was not observed in recipients of either syngeneic (B10) or CD8-depleted allogeneic spleen cells. Furthermore, we analyzed IL-12-treated recipients of EL4 and A/J spleen cells which survived for more than 100 days. No EL4 cells were detected in these mice by flow cytometry, tissue culture, adoptive transfer, necropsies, or histologic examination. Both GVL effects and the inhibitory effect of IL-12 on GVHD were diminished by neutralizing anti-interferon- (IFN- ) monoclonal antibody. This study demonstrates that IL-12-induced IFN- production plays a role in the protective effect of IL-12 against GVHD. Furthermore, IFN- is involved in the GVL effect against EL4 leukemia, demonstrating that protection from CD4-mediated GVHD and CD8-dependent anti-leukemic activity can be provided by a single cytokine, IFN- . These observations may provide the basis for a new approach to inhibiting GVHD while preserving GVL effects of alloreactivity.
Blood, Vol. 90 No. 11 (December 1), 1997:
pp. 4651-4660
© 1997 by The American Society of Hematology.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. D. Kuns, E. S. Morris, K. P. A. MacDonald, K. A. Markey, H. M. Morris, N. C. Raffelt, T. Banovic, A. L. J. Don, V. Rowe, A. C. Burman, et al.
Invariant natural killer T cell-natural killer cell interactions dictate transplantation outcome after {alpha}-galactosylceramide administration
Blood,
June 4, 2009;
113(23):
5999 - 6010.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wang, W. Asavaroengchai, B. Yong Yeap, M.-G. Wang, S. Wang, M. Sykes, and Y.-G. Yang
Paradoxical effects of IFN-{gamma} in graft-versus-host disease reflect promotion of lymphohematopoietic graft-versus-host reactions and inhibition of epithelial tissue injury
Blood,
April 9, 2009;
113(15):
3612 - 3619.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Chakraverty, B. Flutter, F. Fallah-Arani, H.-S. Eom, T. Means, G. Andreola, S. Schwarte, J. Buchli, P. Cotter, G. Zhao, et al.
The Host Environment Regulates the Function of CD8+ Graft-versus-Host-Reactive Effector Cells
J. Immunol.,
November 15, 2008;
181(10):
6820 - 6828.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Yoshida, T. Hirano, G. Son, Y. Iimuro, T. Imado, T. Iwasaki, and J. Fujimoto
Allogeneic bone marrow transplantation for hepatocellular carcinoma: hepatocyte growth factor suppresses graft-vs.-host disease
Am J Physiol Gastrointest Liver Physiol,
December 1, 2007;
293(6):
G1114 - G1123.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wang, B. Grzywacz, D. Sukovich, V. McCullar, Q. Cao, A. B. Lee, B. R. Blazar, D. N. Cornfield, J. S. Miller, and M. R. Verneris
The unexpected effect of cyclosporin A on CD56+CD16 and CD56+CD16+ natural killer cell subpopulations
Blood,
September 1, 2007;
110(5):
1530 - 1539.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Ramirez-Montagut, A. Chow, A. A. Kochman, O. M. Smith, D. Suh, H. Sindhi, S. Lu, C. Borsotti, J. Grubin, N. Patel, et al.
IFN-{gamma} and Fas Ligand Are Required for Graft-versus-Tumor Activity against Renal Cell Carcinoma in the Absence of Lethal Graft-versus-Host Disease
J. Immunol.,
August 1, 2007;
179(3):
1669 - 1680.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Robertson, H.-C. Chang, D. Pelloso, and M. H. Kaplan
Impaired interferon-{gamma} production as a consequence of STAT4 deficiency after autologous hematopoietic stem cell transplantation for lymphoma
Blood,
August 1, 2005;
106(3):
963 - 970.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. S. Krause and R. A. Van Etten
Adoptive immunotherapy of BCR-ABL-induced chronic myeloid leukemia-like myeloproliferative disease in a murine model
Blood,
December 15, 2004;
104(13):
4236 - 4244.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-K. Min, Y. Maeda, K. Lowler, C. Liu, S. Clouthier, D. Lofthus, E. Weisiger, J. L. M. Ferrara, and P. Reddy
Paradoxical effects of interleukin-18 on the severity of acute graft-versus-host disease mediated by CD4+ and CD8+ T-cell subsets after experimental allogeneic bone marrow transplantation
Blood,
November 15, 2004;
104(10):
3393 - 3399.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Imado, T. Iwasaki, Y. Kataoka, T. Kuroiwa, H. Hara, J. Fujimoto, and H. Sano
Hepatocyte growth factor preserves graft-versus-leukemia effect and T-cell reconstitution after marrow transplantation
Blood,
September 1, 2004;
104(5):
1542 - 1549.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. C. Matte, J. Cormier, B. E. Anderson, I. Athanasiadis, J. Liu, S. G. Emerson, W. Pear, and W. D. Shlomchik
Graft-versus-leukemia in a retrovirally induced murine CML model: mechanisms of T-cell killing
Blood,
June 1, 2004;
103(11):
4353 - 4361.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Reddy, Y. Maeda, K. Hotary, C. Liu, L. L. Reznikov, C. A. Dinarello, and J. L. M. Ferrara
Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect
PNAS,
March 16, 2004;
101(11):
3921 - 3926.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Leung, R. Iyengar, V. Turner, P. Lang, P. Bader, P. Conn, D. Niethammer, and R. Handgretinger
Determinants of Antileukemia Effects of Allogeneic NK Cells
J. Immunol.,
January 1, 2004;
172(1):
644 - 650.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. A. Wilcox, K. Tamada, D. B. Flies, G. Zhu, A. I. Chapoval, B. R. Blazar, W. M. Kast, and L. Chen
Ligation of CD137 receptor prevents and reverses established anergy of CD8+ cytolytic T lymphocytes in vivo
Blood,
January 1, 2004;
103(1):
177 - 184.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Ichiba, T. Teshima, R. Kuick, D. E. Misek, C. Liu, Y. Takada, Y. Maeda, P. Reddy, D. L. Williams, S. M. Hanash, et al.
Early changes in gene expression profiles of hepatic GVHD uncovered by oligonucleotide microarrays
Blood,
July 15, 2003;
102(2):
763 - 771.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Orsini, R. Bellucci, E. P. Alyea, R. Schlossman, C. Canning, S. McLaughlin, P. Ghia, K. C. Anderson, and J. Ritz
Expansion of Tumor-specific CD8+ T Cell Clones in Patients with Relapsed Myeloma after Donor Lymphocyte Infusion
Cancer Res.,
May 15, 2003;
63(10):
2561 - 2568.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Reddy, T. Teshima, G. Hildebrandt, D. L. Williams, C. Liu, K. R. Cooke, and J. L.M. Ferrara
Pretreatment of donors with interleukin-18 attenuates acute graft-versus-host disease via STAT6 and preserves graft-versus-leukemia effects
Blood,
April 1, 2003;
101(7):
2877 - 2885.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Robertson, D. Pelloso, R. Abonour, R. A. Hromas, R. P. Nelson Jr., L. Wood, and K. Cornetta
Interleukin 12 Immunotherapy after Autologous Stem Cell Transplantation for Hematological Malignancies
Clin. Cancer Res.,
November 1, 2002;
8(11):
3383 - 3393.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Reddy, T. Teshima, G. Hildebrandt, U. Duffner, Y. Maeda, K. R. Cooke, and J. L. M. Ferrara
Interleukin 18 preserves a perforin-dependent graft-versus-leukemia effect after allogeneic bone marrow transplantation
Blood,
October 16, 2002;
100(9):
3429 - 3431.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Y. Mapara, Y.-M. Kim, S.-P. Wang, R. Bronson, D. H. Sachs, and M. Sykes
Donor lymphocyte infusions mediate superior graft-versus-leukemia effects in mixed compared to fully allogeneic chimeras: a critical role for host antigen-presenting cells
Blood,
August 13, 2002;
100(5):
1903 - 1909.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-G. Yang, J. Qi, M.-G. Wang, and M. Sykes
Donor-derived interferon gamma separates graft-versus-leukemia effects and graft-versus-host disease induced by donor CD8 T cells
Blood,
May 13, 2002;
99(11):
4207 - 4215.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
U. F. Hartwig, M. Robbers, C. Wickenhauser, and C. Huber
Murine acute graft-versus-host disease can be prevented by depletion of alloreactive T lymphocytes using activation-induced cell death
Blood,
April 15, 2002;
99(8):
3041 - 3049.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Liu, B. E. Anderson, M. E. Robert, J. M. McNiff, S. G. Emerson, W. D. Shlomchik, and M. J. Shlomchik
Selective T-cell subset ablation demonstrates a role for T1 and T2 cells in ongoing acute graft-versus-host disease: a model system for the reversal of disease
Blood,
December 1, 2001;
98(12):
3367 - 3375.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Okamoto, K. Kohno, T. Tanimoto, K. Iwaki, T. Ishihara, S. Akamatsu, H. Ikegami, and M. Kurimoto
IL-18 Prevents the Development of Chronic Graft-Versus-Host Disease in Mice
J. Immunol.,
June 1, 2000;
164(11):
6067 - 6074.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. I. Krijanovski, G. R. Hill, K. R. Cooke, T. Teshima, J. M. Crawford, Y. S. Brinson, and J. L.M. Ferrara
Keratinocyte Growth Factor Separates Graft-Versus-Leukemia Effects From Graft-Versus-Host Disease
Blood,
July 15, 1999;
94(2):
825 - 831.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. J. Robertson, C. Cameron, M. B. Atkins, M. S. Gordon, M. T. Lotze, M. L. Sherman, and J. Ritz
Immunological Effects of Interleukin 12 Administered by Bolus Intravenous Injection to Patients with Cancer
Clin. Cancer Res.,
January 1, 1999;
5(1):
9 - 16.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. R. Dey, Y.-G. Yang, G. L. Szot, D. A. Pearson, and M. Sykes
Interleukin-12 Inhibits Graft-Versus-Host Disease Through an Fas-Mediated Mechanism Associated With Alterations in Donor T-Cell Activation and Expansion
Blood,
May 1, 1998;
91(9):
3315 - 3322.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|